Oligonucleotides having a nucleotide sequence complementary to nucleotide
numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596,
2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No.
NM_004006.1) and therapeutic agents for muscular dystrophy comprising
such oligonucleotides.